f) A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX